Slingshot Insights | Kmda Overview

KMDA Overview

Upcoming Projects (KMDA)

2nd View: Examining Emerging Gene-editing Therapies for alpha-1 antitrypsin deficiency (AATD), including Beam Therapeutics' BEAM-302
Tickers: BEAM, TAK, GRFS, KMDA
Execute By: May 31, 2026

Executed Projects (KMDA)

Examining Emerging Gene-editing Therapies for alpha-1 antitrypsin deficiency (AATD), including Beam Therapeutics' BEAM-302
Tickers: BEAM, TAK, GRFS, KMDA
Executed On: Apr 22, 2026 at 10:00 AM EDT

Upcoming & Overdue Catalysts (KMDA)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (KMDA)

KMDA's Phase 2 data for Alpha-1 Antitrypsin for Pediatric Patients newly diagnosed with Type 1 diabetes Expected Q3 2017
Ticker: KMDA
Occurred on: Jan 08, 2018
Kamada and Kedrion announce the filing of a BLA in the U.S. seeking approval of Kamada's post-exposure rabies treatment human anti-rabies immune globulin (IgG); decision expected mid-2017
Ticker: KMDA
Occurred on: Aug 25, 2017
Kamada Meets Primary Endpoint of U.S. Phase 2 Study of Inhaled Alpha-1 Antitrypsin for the Treatment of Alpha-1 Antitrypsin Deficiency
Ticker: KMDA
Occurred on: Aug 30, 2016
Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection
Ticker: KMDA
Occurred on: Apr 07, 2016
Kamada Submits Marketing Authorization Application with the European Medicines Agency for its Proprietary Inhaled Alpha-1 Antitrypsin to Treat Alpha-1 Antitrypsin Deficiency
Ticker: KMDA
Occurred on: Mar 28, 2016

Strategic Initiatives (KMDA)

Shire (SHPG) Extends Kamada's (KMDA) GLASSIA Supply Agreement Through 2020
Tickers: KMDA, SHPG
Announcement Date: Oct 06, 2016